✨ Free AI Report
BioRestorative Therapies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BioRestorative Therapies, Inc.
Company Research

BioRestorative Therapies, Inc.: Business Overview, Financials & Competitive Analysis

BioRestorative Therapies, Inc. (NASDAQ:BRTX) is a late-stage clinical regenerative medicine innovator focused on stem cell-based therapies and products. The company's lead program, BRTX-100, targets chronic lumbar dis...

Analyst-debate audio for BioRestorative Therapies, Inc.

AskCyborg analysts argue the bull and bear cases for BioRestorative Therapies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical inflection point with Phase 2 data momentum, regulatory clarity on BLA pathway, and dual revenue streams from...

Read the full analyst-debate transcript →
Industry Regenerative medicine
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest BioRestorative Therapies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BioRestorative Therapies, Inc. Overview

Pro stress-test →

BioRestorative Therapies, Inc. (NASDAQ:BRTX) is a late-stage clinical regenerative medicine innovator focused on stem cell-based therapies and products. The company's lead program, BRTX-100, targets chronic lumbar disc disease and is transitioning toward late-stage regulatory approval, positioning it as a clinical-stage regenerative medicine company at an inflection point.

Strategic Profile

Pro stress-test →

The company has completed enrollment in its fully powered Phase 2 trial of BRTX-100 and achieved positive Type B regulatory outcome with alignment on the BLA pathway. Beyond its core disc/spine program, BioRestorative operates a commercial BioCosmeceutical platform leveraging exosome technology derived from mesenchymal stem cells for aesthetic and dermatologic applications, creating a dual-track business model spanning clinical development and near-term commercial revenue.

Competitive Landscape

Pro stress-test →

BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells, with core clinical development programs targeting disc/spine disease and metabolic disorders. Competitors include Organogenesis (organ regeneration), Aziyo Biologics (regenerative tissue), and Misonix (surgical innovation), alongside established spine companies like Zimmer Biomet and DePuy Synthes in the adjacent orthopedic market.

Industry Context

BioRestorative Therapies, Inc. operates in Regenerative medicine.

Key facts

Founded: 2009 · Headquarters: Melville, New York, United States · Revenue: Estimated $2M-$8M (primarily biocosmeceuticals pre-BRTX-100 approval)

What the analysts stress-tested

The top findings that survived the multi-agent debate for BioRestorative Therapies, Inc..

  • In May 2026, BRTX-100 Phase 2 data showed 52% of evaluable patients achieved at least 50% improvement in both VAS pain and ODI function measures with no dose-limiting toxicity safety signals, validating efficacy and safety profile ahead of Phase 3 preparation.
  • In 2026, the company prioritized readiness for late-stage development of BRTX-100 by aligning resources to regulatory, manufacturing, and clinical preparation activities, signaling disciplined capital allocation toward commercialization infrastructure.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Completed Phase 2 enrollment in BRTX-100 with positive Type B FDA regulatory outcome and BLA pathway alignment
  • May 2026Presented expanded Phase 2 blinded dataset showing sustained pain and functional improvements in chronic lumbar disc disease at ISCT 2026
  • +1 moreTrack every material event for BioRestorative Therapies, Inc. as it happens. Explore monitoring →
Get alerted when BioRestorative Therapies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Osiris TherapeuticsStem cell-based regenerative medicine therapies→Videregen BiotechnologyCell and tissue engineering for regenerative medicine→MesoblastMesenchymal stem cell-based therapies for inflammatory and degenerative diseases→Nuo TherapeuticsRegenerative medicine products for tissue healing and repair→

Compare BioRestorative Therapies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BioRestorative Therapies, Inc. operates in Regenerative medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Regenerative medicine research →
NEW · MCP server

Ask your AI assistant about BioRestorative Therapies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BioRestorative Therapies, Inc. and its top competitor on Cyborg Score”
“What did BioRestorative Therapies, Inc. do this quarter?”
“Is BioRestorative Therapies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BioRestorative Therapies, Inc. do?+
BioRestorative Therapies, Inc. (NASDAQ:BRTX) is a late-stage clinical regenerative medicine innovator focused on stem cell-based therapies and products. The company's lead program, BRTX-100, targets chronic lumbar dis...
What is BioRestorative Therapies, Inc.'s Cyborg Score?+
BioRestorative Therapies, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BioRestorative Therapies, Inc.'s main competitors?+
Named competitors include Osiris Therapeutics, Videregen Biotechnology, Mesoblast, Nuo Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full BioRestorative Therapies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BioRestorative Therapies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BioRestorative Therapies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Regenerative medicine research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Humacyte, Inc.6TELA Bio, Inc.5Organogenesis Holdings Inc.4Longeveron Inc.7Mesoblast Limited